I like your numbers but $100m revenue won't be achieved in 1-2 years IMO.
To reach that will take some time but if revenues increase substantially each quarter, the market will take notice and revalue this accordingly.
If they can get to $10-$20m revenue for 2017, they will be doing well IMO.
Take a look at Pharmaxis with its EMA approval for Bronchitol. Revenues aren't impressive.
Obv FDA approval will be huge if Clinuvel are successful in Europe.
- Forums
- ASX - By Stock
- Ann: SCENESSE Treatment in Europe-CUV.AX
I like your numbers but $100m revenue won't be achieved in 1-2...
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CUV (ASX) to my watchlist
(20min delay)
|
|||||
Last
$14.74 |
Change
0.190(1.31%) |
Mkt cap ! $724.1M |
Open | High | Low | Value | Volume |
$14.60 | $14.79 | $14.32 | $881.1K | 60.57K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 87 | $14.67 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$14.79 | 2000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 87 | 14.670 |
2 | 288 | 14.640 |
1 | 288 | 14.610 |
2 | 388 | 14.580 |
1 | 288 | 14.560 |
Price($) | Vol. | No. |
---|---|---|
14.790 | 2000 | 1 |
14.820 | 288 | 1 |
14.840 | 288 | 1 |
14.870 | 288 | 1 |
14.900 | 288 | 1 |
Last trade - 16.10pm 10/09/2024 (20 minute delay) ? |
Featured News
CUV (ASX) Chart |